Thalamic noradrenaline in Parkinson's disease: Deficits suggest role in motor and non-motor symptoms

Movement Disorders

Volumn 27, Issue 13, 2012, Pages 1618-1624

  Pifl, Christian ^a   Kish, Stephen J ^b   Hornykiewicz, Oleh ^a  

^a Medical University of Vienna   (Austria)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Noradrenaline; Parkinson's disease; Thalamic nuclei

Indexed keywords

NORADRENALIN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCHEMICAL DETECTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMBIC CORTEX; MALE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SOMATOSENSORY CORTEX; THALAMUS INTRALAMINAR NUCLEUS; THALAMUS NUCLEUS; THALAMUS VENTRAL NUCLEUS;

AGED; AGED, 80 AND OVER; CELL DEATH; FEMALE; HUMANS; MALE; NEURONS; NOREPINEPHRINE; PARKINSON DISEASE; THALAMUS;

EID: 84870357567     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25109     Document Type: Article

References (59)

1. Ehringer H, Hornykiewicz O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr 1960; 38: 1236-1239.
2. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998; 51(2 Suppl 2): S2-S9.
3. Barone P. Neurotransmission in Parkinson's disease: beyond dopamine. Eur J Neurol 2010; 17: 364-376.
4. Evarts EV, Kimura M, Wurtz RH, Hikosaka O. Behavioral correlates of activity in basal ganglia neurons. Trends Neurosci 1984; 7: 447-453.
5. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-375.
6. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-381.
7. Galvan A, Wichmann T. Pathophysiology of parkinsonism. Clin Neurophysiol 2008; 119: 1459-1474.
8. Obeso JA, Marin C, Rodriguez-Oroz C, et al. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol 2008; 64(Suppl 2): S30-S46.
9. Jahnsen H, Llinas R. Electrophysiological properties of guinea-pig thalamic neurones: an in vitro study. J Physiol 1984; 349: 205-226.
10. Steriade M, Deschenes M. The thalamus as a neuronal oscillator. Brain Res 1984; 320: 1-63.
11. Pape HC, McCormick DA. Noradrenaline and serotonin selectively modulate thalamic burst firing by enhancing a hyperpolarization-activated cation current. Nature 1989; 340: 715-718.
12. Lee KH, McCormick DA. Abolition of spindle oscillations by serotonin and norepinephrine in the ferret lateral geniculate and perigeniculate nuclei in vitro. Neuron 1996; 17: 309-321.
13. McCormick DA, Feeser HR. Functional implications of burst firing and single spike activity in lateral geniculate relay neurons. Neuroscience 1990; 39: 103-113.
14. McCormick DA, Pape HC, Williamson A. Actions of norepinephrine in the cerebral cortex and thalamus: implications for function of the central noradrenergic system. Prog Brain Res 1991; 88: 293-305.
15. Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 2003; 42: 33-84.
16. Hirata A, Aguilar J, Castro-Alamancos MA. Noradrenergic activation amplifies bottom-up and top-down signal-to-noise ratios in sensory thalamus. J Neurosci 2006; 26: 4426-4436.
17. Buzsaki G, Kennedy B, Solt VB, Ziegler M. Noradrenergic Control of Thalamic Oscillation: the Role of alpha-2 Receptors. Eur J Neurosci 1991; 3 (3): 222-229.
18. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003; 60: 337-341.
19. Delaville C, Deurwaerdere PD, Benazzouz A. Noradrenaline and Parkinson's disease. Front Syst Neurosci 2011; 5: 31.
20. Farley IJ, Hornykiewicz O. Noradrenaline in subcortical brain regions in patients with Parkinson's disease and control subjects. In: Birkmayer W, Hornykiewicz O, eds. Advances in Parkinsonism. Basle: Editiones Roche; 1976: 178-185.
21. Riley HA. An Atlas of the Basal Ganglia, Brain Stem and the Spinal Cord. New York: Hafner; 1960.
22. Crosby EC, Humphery T, Lauer EW. Correlative Anatomy of the Nervous System. New York: Macmillan; 1962.
23. Carpenter MB. Human Neuroanatomy. Baltimore: Williams & Wilkins Company; 1976.
24. Pifl C, Schingnitz G, Hornykiewicz O. Effect of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 1991; 44: 591-605.
25. Shannak K, Rajput A, Rozdilsky B, Kish S, Gilbert J, Hornykiewicz O. Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res 1994; 639: 33-41.
26. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008; 131 (Pt 1): 120-131.
27. Smith Y, Raju D, Nanda B, Pare JF, Galvan A, Wichmann T. The thalamostriatal systems: anatomical and functional organization in normal and parkinsonian states. Brain Res Bull 2009; 78 (2-3): 60-68.
28. Henderson JM, Carpenter K, Cartwright H, Halliday GM. Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann Neurol 2000; 47: 345-352.
29. Oke AF, Carver LA, Gouvion CM, Adams RN. Three-dimensional mapping of norepinephrine and serotonin in human thalamus. Brain Res 1997; 763: 69-78.
30. Lindvall O, Bjorklund A, Nobin A, Stenevi U. The adrenergic innervation of the rat thalamus as revealed by the glyoxylic acid fluorescence method. J Comp Neurol 1974; 154: 317-347.
31. Gerlach M, Gsell W, Kornhuber J, et al. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res 1996; 741 (1-2): 142-152.
32. Pessiglione M, Guehl D, Rolland AS, et al. Thalamic neuronal activity in dopamine-depleted primates: evidence for a loss of functional segregation within basal ganglia circuits. J Neurosci 2005; 25: 1523-1531.
33. Rivlin-Etzion M, Marmor O, Heimer G, Raz A, Nini A, Bergman H. Basal ganglia oscillations and pathophysiology of movement disorders. Curr Opin Neurobiol 2006; 16: 629-637.
34. Brown P. Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease. Mov Disord 2003; 18: 357-363.
35. Hammond C, Bergman H, Brown P. Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci 2007; 30: 357-364.
36. Kaneoke Y, Vitek J. The motor thalamus in the Parkinsonian primate: enhanced burst and oscillatory activities. Abstr Soc Neurosci 1995; 21 (1-3): 1428.
37. Magnin M, Morel A, Jeanmonod D. Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in parkinsonian patients. Neuroscience 2000; 96: 549-564.
38. Zirh TA, Lenz FA, Reich SG, Dougherty PM. Patterns of bursting occurring in thalamic cells during parkinsonian tremor. Neuroscience 1998; 83: 107-121.
39. Molnar GF, Pilliar A, Lozano AM, Dostrovsky JO. Differences in neuronal firing rates in pallidal and cerebellar receiving areas of thalamus in patients with Parkinson's disease, essential tremor, and pain. J Neurophysiol 2005; 93: 3094-3101.
40. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15(Suppl 1): 14-20.
41. Schmahmann JD. Vascular syndromes of the thalamus. Stroke 2003; 34: 2264-2278.
42. Foote SL, Bloom FE, Aston-Jones G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev 1983; 63: 844-914.
43. Rajkowski J, Kubiak P, Aston-Jones G. Locus coeruleus activity in monkey: phasic and tonic changes are associated with altered vigilance. Brain Res Bull 1994; 35 (5-6): 607-616.
44. Usher M, Cohen JD, Servan-Schreiber D, Rajkowski J, Aston-Jones G. The role of locus coeruleus in the regulation of cognitive performance. Science 1999; 283: 549-554.
45. LaBerge D, Buchsbaum MS. Positron emission tomographic measurements of pulvinar activity during an attention task. J Neurosci 1990; 10: 613-619.
46. Frith CD, Friston KJ. The role of the thalamus in "top down" modulation of attention to sound. Neuroimage 1996; 4 (3 Pt 1): 210-215.
47. Portas CM, Rees G, Howseman AM, Josephs O, Turner R, Frith CD. A specific role for the thalamus in mediating the interaction of attention and arousal in humans. J Neurosci 1998; 18: 8979-8989.
48. Coull JT, Jones ME, Egan TD, Frith CD, Maze M. Attentional effects of noradrenaline vary with arousal level: selective activation of thalamic pulvinar in humans. Neuroimage 2004; 22: 315-322.
49. Robbins TW, Everitt BJ. Central norepinephrine neurons and behavior. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The fourth generation of progress. New York: Raven Press, Ltd.; 1995: 363-372.
50. Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 2009; 10: 211-223.
51. Hartman BK, Zide D, Udenfriend S. The use of dopamine -hydroxylase as a marker for the central noradrenergic nervous system in rat brain. Proc Natl Acad Sci U S A 1972; 69: 2722-2726.
52. Sandor P. Nervous control of the cerebrovascular system: doubts and facts. Neurochem Int 1999; 35: 237-259.
53. Raichle ME, Hartman BK, Eichling JO, Sharpe LG. Central noradrenergic regulation of cerebral blood flow and vascular permeability. Proc Natl Acad Sci U S A 1975; 72: 3726-3730.
54. Birkmayer W, Hornykiewicz O. [The L-3, 4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr 1961; 73: 787-788.
55. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-379.
56. Young AB. Four decades of neurodegenerative disease research: how far we have come! J Neurosci 2009; 29: 12722-12728.
57. Chalmers JP, Baldessarini RJ, Wurtman RJ. Effects of L-dopa on norepinephrine metabolism in the brain. Proc Natl Acad Sci U S A 1971; 68: 662-666.
58. Mercuri NB, Bernardi G. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol Sci 2005; 26: 341-344.
59. Schapira AH, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson's disease. Eur J Neurol 2009; 16: 982-989.